uric acid has been researched along with Multiple System Atrophy in 14 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Multiple System Atrophy: A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this trial was to investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'-monophosphate (IMP) in multiple system atrophy (MSA)." | 9.41 | Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study). ( Eun Lee, J; Han Yoon, J; Hyu Lee, P; Hyun Lee, Y; Jin Kim, S; Jong Chung, S; Jung Lee, J; Keun Song, S; Sam Baik, J; Shin, HW; Sohn, YH; Soo Yoo, H; Sunwoo, M; Yong Hong, J; Yun Kang, S, 2021) |
| "We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores." | 7.77 | Uric acid as a potential disease modifier in patients with multiple system atrophy. ( Lee, JE; Lee, PH; Sohn, YH; Song, SK, 2011) |
| "Uric acid has an anti-oxidative effect." | 5.42 | Association of serum uric acid level with cognitive function among patients with multiple system atrophy. ( Cao, B; Ou, R; Shang, HF; Wei, QQ; Yang, J, 2015) |
| "The aim of this trial was to investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'-monophosphate (IMP) in multiple system atrophy (MSA)." | 5.41 | Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study). ( Eun Lee, J; Han Yoon, J; Hyu Lee, P; Hyun Lee, Y; Jin Kim, S; Jong Chung, S; Jung Lee, J; Keun Song, S; Sam Baik, J; Shin, HW; Sohn, YH; Soo Yoo, H; Sunwoo, M; Yong Hong, J; Yun Kang, S, 2021) |
| "Uric acid has an antioxidative effect." | 5.39 | Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population. ( Cao, B; Chen, K; Guo, X; Huang, R; Shang, HF; Song, W; Wei, QQ; Zhao, B, 2013) |
| "Serum uric acid (UA) levels are reported to be decreased in patients with Parkinson's disease (PD) and multiple system atrophy (MSA)." | 3.85 | Serum uric acid levels in Parkinson's disease and related disorders. ( Fujita, H; Hirata, K; Miyamoto, M; Miyamoto, T; Numao, A; Sakuta, H; Suzuki, K; Watanabe, Y, 2017) |
| "We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores." | 3.77 | Uric acid as a potential disease modifier in patients with multiple system atrophy. ( Lee, JE; Lee, PH; Sohn, YH; Song, SK, 2011) |
| "Uric acid (UA) is an important endogenous antioxidant that protects against oxidative stress, yet its exact role in neurodegeneration remains unclear." | 1.72 | Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study. ( Aerqin, Q; Chen, KL; Chen, SF; Dong, Q; Huang, YY; Jia, SS; Li, Q; Ou, YN; Shen, XN; Yu, JT, 2022) |
| "Uric acid is a natural antioxidant, and it has been shown that low levels of uric acid could be a risk factor for the development of PD." | 1.43 | Low serum uric acid levels in progressive supranuclear palsy. ( Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Gómez-Garre, P; Huertas-Fernández, I; Jesús, S; Mir, P; Oropesa-Ruiz, JM; Vargas-Gonzalez, L, 2016) |
| "Uric acid has an anti-oxidative effect." | 1.42 | Association of serum uric acid level with cognitive function among patients with multiple system atrophy. ( Cao, B; Ou, R; Shang, HF; Wei, QQ; Yang, J, 2015) |
| "Uric acid has an antioxidative effect." | 1.39 | Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population. ( Cao, B; Chen, K; Guo, X; Huang, R; Shang, HF; Song, W; Wei, QQ; Zhao, B, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Aerqin, Q | 1 |
| Jia, SS | 1 |
| Shen, XN | 1 |
| Li, Q | 1 |
| Chen, KL | 1 |
| Ou, YN | 1 |
| Huang, YY | 1 |
| Dong, Q | 1 |
| Chen, SF | 1 |
| Yu, JT | 1 |
| Yoo, HS | 1 |
| Chung, SJ | 1 |
| Lee, YH | 1 |
| Ye, BS | 1 |
| Sohn, YH | 3 |
| Kwon, H | 1 |
| Lee, PH | 2 |
| Jung Lee, J | 1 |
| Han Yoon, J | 1 |
| Jin Kim, S | 1 |
| Soo Yoo, H | 1 |
| Jong Chung, S | 1 |
| Hyun Lee, Y | 1 |
| Yun Kang, S | 1 |
| Shin, HW | 1 |
| Keun Song, S | 1 |
| Yong Hong, J | 1 |
| Sunwoo, M | 1 |
| Eun Lee, J | 1 |
| Sam Baik, J | 1 |
| Hyu Lee, P | 1 |
| Fukae, J | 1 |
| Fujioka, S | 1 |
| Yanamoto, S | 1 |
| Mori, A | 1 |
| Nomi, T | 1 |
| Hatano, T | 1 |
| Fukuhara, K | 1 |
| Ouma, S | 1 |
| Hattori, N | 1 |
| Tsuboi, Y | 1 |
| Zhang, X | 1 |
| Liu, DS | 1 |
| An, CY | 1 |
| Liu, YZ | 1 |
| Liu, XH | 1 |
| Zhang, F | 1 |
| Ning, LN | 1 |
| Li, CL | 1 |
| Ma, CM | 1 |
| Hu, RT | 1 |
| Cao, B | 2 |
| Guo, X | 1 |
| Chen, K | 1 |
| Song, W | 1 |
| Huang, R | 1 |
| Wei, QQ | 2 |
| Zhao, B | 1 |
| Shang, HF | 2 |
| Ou, R | 1 |
| Yang, J | 1 |
| Oropesa-Ruiz, JM | 1 |
| Huertas-Fernández, I | 1 |
| Jesús, S | 1 |
| Cáceres-Redondo, MT | 1 |
| Vargas-Gonzalez, L | 1 |
| Carrillo, F | 1 |
| Carballo, M | 1 |
| Gómez-Garre, P | 1 |
| Mir, P | 1 |
| Zhou, L | 1 |
| Jiang, Y | 1 |
| Zhu, C | 1 |
| Ma, L | 1 |
| Huang, Q | 1 |
| Chen, X | 1 |
| Sakuta, H | 1 |
| Suzuki, K | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Numao, A | 1 |
| Fujita, H | 1 |
| Watanabe, Y | 1 |
| Hirata, K | 1 |
| Kim, HJ | 1 |
| Jeon, BS | 1 |
| Lee, JY | 1 |
| Lee, JE | 1 |
| Song, SK | 1 |
| Constantinescu, R | 1 |
| Andreasson, U | 1 |
| Holmberg, B | 1 |
| Zetterberg, H | 1 |
| Fitzmaurice, PS | 1 |
| Ang, L | 1 |
| Guttman, M | 1 |
| Rajput, AH | 1 |
| Furukawa, Y | 1 |
| Kish, SJ | 1 |
1 review available for uric acid and Multiple System Atrophy
| Article | Year |
|---|---|
Association between serum uric acid level and multiple system atrophy: A meta-analysis.
Topics: Biomarkers; Case-Control Studies; China; Cohort Studies; Cross-Sectional Studies; Female; Humans; Ma | 2018 |
1 trial available for uric acid and Multiple System Atrophy
| Article | Year |
|---|---|
Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study).
Topics: Aged; Female; Humans; Inosine Monophosphate; Male; Middle Aged; Multiple System Atrophy; Treatment O | 2021 |
12 other studies available for uric acid and Multiple System Atrophy
| Article | Year |
|---|---|
Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study.
Topics: Alzheimer Disease; Cross-Sectional Studies; Frontotemporal Dementia; Humans; Multiple System Atrophy | 2022 |
Urate is closely linked to white matter integrity in multiple system atrophy.
Topics: Aged; Cerebral Cortex; Diffusion Tensor Imaging; Female; Humans; Male; Middle Aged; Multiple System | 2020 |
Serum uric acid level is linked to the disease progression rate in male patients with multiple system atrophy.
Topics: Aged; Disease Progression; Female; Humans; Male; Middle Aged; Multiple System Atrophy; Sex Factors; | 2017 |
Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population.
Topics: Aged; Chi-Square Distribution; China; Disease Progression; Female; Humans; Male; Middle Aged; Multip | 2013 |
Association of serum uric acid level with cognitive function among patients with multiple system atrophy.
Topics: Aged; Analysis of Variance; Cognition Disorders; Female; Humans; Male; Middle Aged; Multiple System | 2015 |
Low serum uric acid levels in progressive supranuclear palsy.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple System | 2016 |
Oxidative Stress and Environmental Exposures are Associated with Multiple System Atrophy in Chinese Patients.
Topics: Aged; Bilirubin; China; Disability Evaluation; Environmental Exposure; Female; Homocysteine; Humans; | 2016 |
Serum uric acid levels in Parkinson's disease and related disorders.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple System | 2017 |
Serum urate levels are not associated with survival in multiple system atrophy.
Topics: Aged; Female; Humans; Longitudinal Studies; Male; Middle Aged; Multiple System Atrophy; Retrospectiv | 2011 |
Uric acid as a potential disease modifier in patients with multiple system atrophy.
Topics: Enzyme Assays; Female; Humans; Male; Middle Aged; Multiple System Atrophy; Prospective Studies; Regr | 2011 |
Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cross-Sectional Studies; Female; Humans; Male; Middle Ag | 2013 |
Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
Topics: Aged; Antioxidants; Glutathione; Humans; Multiple System Atrophy; Oxidative Stress; Parkinson Diseas | 2003 |